Zhongyuan Union Cell & Gene Engineering (SHSE:600645) DeferredTaxAndRevenue: ¥0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600645 Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
66 GF Score
Price ¥18.77
GF Value ¥20.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zhongyuan Union Cell & Gene Engineering DeferredTaxAndRevenue?

Zhongyuan Union Cell & Gene Engineering SHSE:600645 +1.02% 66 DeferredTaxAndRevenue is ¥0 Mil as of Mar. 2026. GuruFocus rates SHSE:600645 with a GF Score™ of 66/100 and a GF Value™ of ¥20.62 (Fairly Valued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zhongyuan Union Cell & Gene Engineering's current deferred tax and revenue for the quarter that ended in Mar. 2026 was ¥0 Mil.

Zhongyuan Union Cell & Gene Engineering DeferredTaxAndRevenue Related Terms

Zhongyuan Union Cell & Gene Engineering DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Zhongyuan Union Cell & Gene Engineering's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhongyuan Union Cell & Gene Engineering DeferredTaxAndRevenue Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:600645
66GF Score
Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of ¥0 Mil mean?
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a DeferredTaxAndRevenue of ¥0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Zhongyuan Union Cell & Gene Engineering.
Is Zhongyuan Union Cell & Gene Engineering's DeferredTaxAndRevenue too high?
Zhongyuan Union Cell & Gene Engineering's current DeferredTaxAndRevenue is ¥0 Mil. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's DeferredTaxAndRevenue compare to VRTX and REGN?
Zhongyuan Union Cell & Gene Engineering's DeferredTaxAndRevenue of ¥0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Zhongyuan Union Cell & Gene Engineering. Zhongyuan Union Cell & Gene Engineering's current DeferredTaxAndRevenue is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.62, compared to a current price of ¥18.77 — trading 9% below its estimated fair value. The current DeferredTaxAndRevenue is ¥0 Mil. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current DeferredTaxAndRevenue is ¥0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?

Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued. The current stock price of ¥18.77 is trading 9% below its estimated GF Value™ of ¥20.62. GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Fairly Valued.

Key valuation signals for SHSE:600645:

  • DeferredTaxAndRevenue: ¥0 Mil
  • GF Value™: ¥20.62 vs. price of ¥18.77 (9% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhongyuan Union Cell & Gene Engineering Business Description

Address 45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
66GF Score

Get the complete analysis for SHSE:600645

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥18.77
Price
¥20.62
GF Value